Zie ook in gerelateerde artikelen

28 februari 2022: Bron: Harvard en Mediwiet

Op de website van mediwiet een lang artikel over de tussenresultaten van medicinaal cannabis gebruik uit een kleine observatiestudie die wordt uitgevoerd aan de Harvard universiteit. Maar hoewel er maar totaal 37 patiënten met chronische pijn worden gevolgd in deze observatie studie zijn de tussenresultaten toch wel opmerkelijk positief voor de medicinale cannabis, maar wel bij maar een paar patiënten. 
Deze tussentijdse analyses omvatten 37 patiënten met chronische pijn die werden geëvalueerd voorafgaand aan de start van de Medicinale Cannabis behandeling en na 3 en 6 maanden Medicinaal Cannabis gebruik; pijn, klinische toestand, slaap, kwaliteit van leven en conventioneel medicatiegebruik werden beoordeeld.
Daarnaast werden ook bij 9 controlepatiënten die geen medicinale cannabis gebruikten beoordeeld volgens dezelfde meetpunten.
Ten opzichte van de baselinemetingen vertoonden Medicinale cannabis patiënten na 3 en 6 maanden behandeling verbeteringen in pijn die gepaard gingen met verbeterde slaap, stemming, angst en kwaliteit van leven, en stabiel conventioneel medicatiegebruik. Verminderde pijn werd geassocieerd met verbeteringen in aspecten van stemming en angst. De resultaten suggereren over het algemeen dat verhoogde THC-blootstelling verband hield met pijngerelateerde verbetering, terwijl verhoogde CBD-blootstelling verband hield met een verbeterde stemming. In de controlegroep werden geen verbeteringen gezien. 

De studie is in april 2021 gepubliceerd, abstract staat onderaan artikel: No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms

Een vergelijkbare studie of misschein wel dezelfde is deze, zie ook abstract verderop in dit artikel: 

Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA)


Ik geef hier maar het artikel op de website van mediwiet omdat zij goed kunnen uitleggen hoe medicinale cannabis werkt en ook nog andere studies citeren. Voor alle duidelijkheid wij hebben geen enkel contact met mediwiet en wat zij schrijven en aanbieden is volledig voor hun verantwoording. Zie ook onze disclaimer

Harvard studie: chronische pijnpatiënten zien langdurig succes met medicinale cannabis

Nieuw onderzoek van de Harvard Medical School en het Mclean Hospital in Boston wijst uit wat miljoenen pijnpatiënten over de hele wereld uit eigen ondervinding weten: patiënten met chronische pijn ervaren een aanhoudende verbetering van hun symptomen door het gebruik van medicinale cannabis. 

Pijnpatiënten langdurig gemonitord

De studie ‘No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms’ zal worden gepubliceerd in het tijdschrift Experimental and Clinical Psychopharmacology. Een samenvatting verscheen begin april online. 37 patiënten met chronische pijn die medicinale cannabis gebruiken worden langdurig gevolgd voor het onderzoek. Het gaat vooral om mensen met musculoskeletale pijn of neuropathie.

De onderzoekers kijken onder meer naar pijn, slaap, kwaliteit van leven en gebruik van reguliere medicijnen vóór het begin van de behandeling met medicinale cannabis en daarna met een vaste regelmaat van drie maanden. Een controlegroep met pijnpatiënten die reguliere medicijnen kregen en géén medicinale cannabis werd geanalyseerd bij het begin van de onderzoeksperiode – de baseline – en na drie maanden.>>>>>>>>>lees verder artikel op website van mediwiet. 

[Bronnen:
Research Shows Chronic Pain Patients See Sustained Improvement With Cannabis Use, HighTimes.com, 9 april 2021
Study: Cannabis Associated with Sustained Improvements in Chronic Pain Patients, NORML.org, 8 april 2021
Analysis: Medical Cannabis Most Commonly Recommended for Treating Chronic Pain Conditions, NORML.org, 11 februari 2021]

Abstract

In response to the need of more rigorous data on medical cannabis and chronic pain, we conducted a 3-month prospective study incorporating ecological momentary assessment (EMA) to examine the effects of medical cannabis on pain, anxiety/depression, sleep, and quality of life. Data were collected from 46 adults (Mean age=55.7±11.9, 52.2% male) newly initiating medical cannabis treatment for chronic pain. Participants completed a baseline survey, EMA for approximately 1 week pre- and up to 3 weeks post- medical cannabis treatment, and a 3-month follow-up survey. The self-reported EMA data (2535 random and 705 daily assessments) indicated significant reductions in momentary pain intensity (b = −16.5, p < .001, 16.5 points reduction on 0–100 visual analog) and anxiety (b = −0.89, p < .05), and significant increase in daily sleep duration (b = 0.34, p < .01) and sleep quality (b = 0.32, p <.001) after participants initiated medical cannabis for a few weeks. At 3 months, self-reported survey data showed significantly lower levels of worst pain (t = −2.38, p < .05), pain interference (t = −3.82, p < .05), and depression (t = −3.43, p < .01), as well as increased sleep duration (t = 3.95, p < .001), sleep quality (t = −3.04, p < .01), and quality of life (t = 4.48, p 


Observational Study
 
. 2021 Apr;29(2):147-156.
 doi: 10.1037/pha0000435. Epub 2021 Mar 25.

No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms

Affiliations 

Abstract

Previous studies have demonstrated improvements in pain following short-term medical cannabis (MC) use, suggesting long-term MC treatment may alleviate symptoms associated with chronic pain. The goal of this observational and longitudinal study was to examine patients using MC to treat chronic pain pre versus post MC treatment. These interim analyses included 37 patients with chronic pain evaluated prior to initiation of MC treatment and following 3 and 6 months of MC use; pain, clinical state, sleep, quality of life, and conventional medication use were assessed. Correlation analyses examined the relationship between changes in pain and other clinical measures, assessed the impact of cannabinoid exposure on pain and clinical ratings, and assessed whether baseline cannabis expectancies influenced outcome variables. Additionally, a pilot group of treatment-as-usual patients (n = 9) who did not use MC were examined at baseline and 3 months later. Relative to baseline, following 3 and 6 months of treatment, MC patients exhibited improvements in pain which were accompanied by improved sleep, mood, anxiety, and quality of life, and stable conventional medication use. Reduced pain was associated with improvements in aspects of mood and anxiety. The results generally suggest increased THC exposure was related to pain-related improvement, while increased CBD exposure was related to improved mood. Cannabis expectancies were not related to observed improvements. Pilot analyses revealed that treatment-as-usual patients do not demonstrate the same pattern of improvement. Findings highlight the potential efficacy of MC treatment for pain and underscore the unique impact of individual cannabinoids on specific aspects of pain and comorbid symptoms. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

Similar articles

Cited by 1 article

REFERENCES

  • Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki D, Cella D, Rothrock N, Keefe F, Callahan L, & Lai JS (2010). Development of a PROMIS item bank to measure pain interferencePain150(1), 173–182. [PMC free article] [PubMed[]
  • Bates D, Mächler M, Bolker B, & Walker S (2015). Fitting linear mixed-effects models using lme4Journal of Statistical Software67(1), 1–48. []
  • Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, & Clauw DJ (2019). Pills to pot: Observational analyses of cannabis substitution among medical cannabis users with chronic painThe Journal of Pain20 (7), 830–841. [PubMed[]
  • Bolger N, & Laurenceau J-P (2013). Intensive Longitudinal Methods: An Introduction to Diary and Experience Sampling Research. Guilford Publications. []
  • Bomyea J, Lang A, Craske MG, Chavira DA, Sherbourne CD, Rose RD, Golinelli D, Campbell-Sills L, Welch SS, Sullivan G, Bystritsky A, Roy-Byrne P, & Stein MB (2015). Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management programPsychiatry Research229(1–2), 133–142. [PMC free article] [PubMed[]
  • Brown JD, Costales B, van Boemmel-Wegmann S, Goodin AJ, Segal R, & Winterstein AG (2020). Characteristics of older adults who were early adopters of medical cannabis in the Florida Medical Marijuana Use RegistryJournal of Clinical Medicine9(4). [PMC free article] [PubMed[]
  • Buysse DJ, Reynolds CF, Monk TH, Berman SR, & Kupfer DJ (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and researchPsychiatry Research28(2), 193–213. [PubMed[]
  • Cain AE, Depp CA, & Jeste DV (2009). Ecological momentary assessment in aging research: a critical reviewJournal of Psychiatric Research43(11), 987–996. [PMC free article] [PubMed[]
  • Cleeland CS, & Ryan KM (1994). Pain assessment: global use of the Brief Pain InventoryAnnals of the Academy of Medicine Singapore(23), 2. [PubMed[]
  • Cleeland CS (2009). The Brief Pain Inventory User Guide. Retrieved July 7, 2021, from https://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf
  • Cleveland WS (1979). Robust locally weighted regression and smoothing scatterplotsJournal of the American Statistical Association74(368), 829–836. []
  • Cooke AC, Knight KR, & Miaskowski C (2019). Patients’ and clinicians’ perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary careThe International Journal on Drug Policy63, 23–28. [PMC free article] [PubMed[]
  • Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, Kerns R, Von Korff M, Porter L, & Helmick C (2018). Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016MMWR.Morbidity and Mortality Weekly Report67(36), 1001–1006. [PMC free article] [PubMed[]
  • Derogatis LR, & Melisaratos N (1983). The Brief Symptom Inventory: an introductory reportPsychological Medicine13(3), 595–605. [PubMed[]
  • Deshpande A, Mailis-Gagnon A, Zoheiry N, & Lakha SF (2015). Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trialsCanadian Family Physician Medecin de Famille Canadien61(8), E372–E381. [PMC free article] [PubMed[]
  • Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, & IMMPACT. (2005). Core outcome measures for chronic pain clinical trials: IMMPACT recommendationsPain113(1–2), 9–19. [PubMed[]
  • Dyer O (2019). Access to medical marijuana does not reduce opioid overdoses in US, study findsBMJ (Clinical research ed.)365, l4188. [PubMed[]
  • Emery NN, Carpenter RW, Treloar Padovano H, & Miranda R (2020). Why don’t they stop? Understanding unplanned marijuana use among adolescents and young adultsPsychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors34(5), 579–589. [PMC free article] [PubMed[]
  • Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, & Eccleston C (2021). Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trialsPain162(Suppl 1), S45–S66. [PubMed[]
  • Florida Department of Health. (2020). Office of Medical Marijuana Use (OMMU) weekly updateshttps://knowthefactsmmj.com/about/weekly-updates/
  • Gruber SA, Smith RT, Dahlgren MK, Lambros AM, & Sagar KA (2021). No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptomsExperimental and Clinical Psychopharmacology29(2), 147–156. [PubMed[]
  • IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia (2021). International Association for the Study of Pain Presidential Task Force on cannabis and cannabinoid analgesia position statementPain162(Suppl 1), S1–S2. [PubMed[]
  • Kaptchuk TJ (2002). The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Annals of Internal Medicine136(11), 817–825. [PubMed[]
  • Kroenke K, Spitzer RL, & Williams JB (2001). The PHQ-9: validity of a brief depression severity measureJournal of General Internal Medicine16(9), 606–613. [PMC free article] [PubMed[]
  • Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, & Mokdad AH (2009). The PHQ-8 as a measure of current depression in the general populationJournal of Affective Disorders114(1–3), 163–173. [PubMed[]
  • Lev-Ran S, Roerecke M, Le Foll B, George T, McKenzie K, & Rehm J (2013). The Association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studiesEuropean Psychiatry28(S1), 1–1. []
  • Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, & Herzberg PY (2008). Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general populationMedical Care46(3), 266–274. [PubMed[]
  • May M, Junghaenel DU, Ono M, Stone AA, & Schneider S (2018). Ecological momentary assessment methodology in chronic pain research: A systematic reviewThe Journal of Pain19(7), 699–716. [PMC free article] [PubMed[]
  • National Academies of Sciences, Engineering, and Medicine. (2017). In The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. []
  • R Development Core Team (2019). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. []
  • Salaffi F, Stancati A, Silvestri CA, Ciapetti A, & Grassi W (2004). Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scaleEuropean Journal of Pain (London, England)8(4), 283–291. [PubMed[]
  • Salas-Wright CP, Vaughn MG, Cummings-Vaughn LA, Holzer KJ, Nelson EJ, AbiNader M, & Oh S (2017). Trends and correlates of marijuana use among late middle-aged and older adults in the United States, 2002–2014Drug and Alcohol Dependence171, 97–106. [PMC free article] [PubMed[]
  • SAS Institute, Cary, NC. (2013). The SAS system for Windows. Release 9.4 SAS Institute, Cary, NC. []
  • Segura LE, Mauro CM, Levy NS, Khauli N, Philbin MM, Mauro PM, & Martins SS (2019). Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorderJAMA Network Open2(7), e197216. [PMC free article] [PubMed[]
  • Shah A, Hayes CJ, Lakkad M, & Martin BC (2019). Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid useJ General Internal Medicine34(8), 1419–1426. [PMC free article] [PubMed[]
  • Shiffman S, Stone AA, & Hufford MR (2008). Ecological momentary assessmentAnnual Review of Clinical Psychology4, 1–32. [PubMed[]
  • Spitzer RL, Kroenke K, Williams JB, & Lowe B (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7Archives of Internal Medicine166(10), 1092–1097. [PubMed[]
  • Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, Murnion B, Farrell M, Weier M, & Degenhardt L (2018). Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studiesPain159(10), 1932–1954. [PubMed[]
  • Tomás JM, Galiana L, & Fernández I (2018). The SF-8 Spanish Version for Health-Related Quality of Life assessment: Psychometric study with IRT and CFA modelsThe Spanish Journal of Psychology21, E1. [PubMed[]
  • Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, & Witter J (2003). Core outcome domains for chronic pain clinical trials: IMMPACT recommendationsPain106(3), 337–345. [PubMed[]
  • Volkow ND, Baler RD, Compton WM, & Weiss SRB (2014). Adverse health effects of marijuana useNew England Journal of Medicine370(23), 2219–2227. [PMC free article] [PubMed[]
  • Volkow ND, & Weiss SRB (2020). Importance of a standard unit dose for cannabis researchAddiction (Abingdon, England)115(7), 1219–1221. [PMC free article] [PubMed[]
  • Vyas MB, LeBaron VT, & Gilson AM (2018). The use of cannabis in response to the opioid crisis: A review of the literatureNursing Outlook66(1), 56–65. [PubMed[]
  • Ware J, Kosinski M, Dewey J, & Gandek B (2001). How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8 Health Survey. Quality Metric Incorporated. []
  • Wen H, & Hockenberry JM (2018). Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid EnrolleesJAMA Internal Medicine178(5), 673–679. [PMC free article] [PubMed[]
  • Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, & Kleijnen J (2015). Cannabinoids for medical use: A systematic review and meta-analysisJAMA313(24), 2456–2473. [PubMed[]
  • Wilson KG, Eriksson MY, D’Eon JL, Mikail SF, & Emery PC (2002). Major depression and insomnia in chronic painThe Clinical Journal of Pain18(2), 77–83. [PubMed[]

Plaats een reactie ...

Reageer op "Medicinale cannabis verlicht langdurig pijn bij patienten met chronische pijn, blijkt uit kleine Harvard studie."


Gerelateerde artikelen
 

Gerelateerde artikelen

Medicinale cannabis verlicht >> UMCG Groningen gaat onderzoek >> Nieuwe overzichtsstudie van >> Medicinale wiet (cannabis >> Cannabis gebruik met hoge >> Recreatief gebruik van marihuana >> 80 procent van amerikaanse >> DE WATERKOKER VAN MIJN TANTE >> Waar kan ik marihuana of >> Cannabisstofjes CBD en THC >>